Zymeworks (ZYME) and Jazz Pharmaceuticals (JAZZ) said Thursday they have received accelerated approval for Ziihera from the US Food and Drug Administration to treat adult patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer.
The regulator's approval was based on the HERIZON-BTC-01 trial of Ziihera, which evaluated zanidatamab as a single agent in previously treated HER2-positive biliary tract cancer, the companies added. The trial attained its primary endpoint of a confirmed objective response rate.
The partners are currently carrying out the Phase 3 HERIZON-BTC-302 confirmatory trial to evaluate zanidatamab with standard-of-care therapy against standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.
Zymeworks struck a deal with Jazz's Ireland unit in late 2022 to develop and commercialize zanidatamab throughout all indications in the US, Europe, Japan, and all other regions except for those Asia Pacific territories previously licensed by Zymeworks, the companies said.
Shares of Zymeworks were up 4.5% in recent Thursday premarket activity, while Jazz's stock rose 4.4%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。